

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 018733-1055

In re patent application of

Group Art Unit: 1642

David M. Goldenberg, et al.

Serial No. 09/924,103

Examiner: Christopher H. Yaen

Filed: August 8, 2001

For: IMMUNOTHERAPY FOR CHRONIC MYELOIDIC LEUKEMIA

RECEIVED
TECH CENTER 1500/2300
02 MAY 23 PM 2:52

**REQUEST FOR ACKNOWLEDGEMENT OF
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
Washington, D.C. 20231

Attn: Examiner C. Yaen
Art Unit: 1642

Sir:

We received an Office Action (Paper No. 5) dated March 8, 2002 and filed a response on May 8, 2002 on the above captioned application.

However, in reviewing the Office Action Summary, it was noted that we have not received acknowledgement of the Information Disclosure Statement and the five references that were submitted on February 7, 2002. Copy of the postcard stamped by the Patent Office for this submittal is attached. Dr. Christal Sheppard of our office contacted Examiner Yaen via telephone on May 9, 2002 regarding this matter. Examiner Yaen checked the file and informed us that he has the Information Disclosure Statement but the references were not in the file.

Applicants are hereby re-submitting, via courier, copies of the references that were cited in the aforementioned Information Disclosure Statement. Applicants respectfully request for an appropriately acknowledged PTO-1449.

Respectfully submitted,

Date May 22, 2002

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5300
Facsimile: (202) 672-5399

By Stephen B. Maebius by
Charles F. Schmitt
Stephen B. Maebius Reg. No. 27,590
Attorney for Applicants
Registration No. 35,264

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 018733-1055	SERIAL NO. 09/924,103
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT David M. GOLDENBERG, et al.	
		FILING DATE 08/08/2001	GROUP ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A1	2,279,474	01/31/2000	Canada				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A2	P. Caron et al., "Supersaturating Infusional Humanized Anti-CD33 Monoclonal Antibody HuM195 in Myelogenous Leukemia ¹ ," <u>Clinical Cancer Research</u> , Vol. 4, pgs. 1421-1428, June 1998.						
	A3	H. Hansen et al., "Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen," <u>Cancer</u> , Vol. 71, No. 11, pgs. 3478-3485, June 1993.						
	A4	J. Kotzerke et al., "Use of Re-188-Labeled Anti NCA-95 Antibodies in Treatment of Leukemia: First Results," <u>Journal of Nuclear Medicine</u> , Vol. 40, No. 5, May 1999, Abstract.						
	A5	R. Di Noto et al., "In Vitro Treatment of APL Cells with Arsenic Trioxide (As ₂ O ₃) Results in a Highly Specific Induction of Solitary CD66c Display," <u>Blood</u> , Vol. 90, No. 10, November 1997, Abstract.						

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.